Navigation Links
Ambien CR(R) (zolpidem tartrate extended-release) tablets CIV Improved Chronic Insomnia in Patients with Co-Morbid Generalized Anxiety Disorder
Date:1/4/2008

Improved Sleep Quality and Sleep Impact on Daily Activities in GAD Patients

Total sleep time was increased in the Ambien CR group throughout the study. At Week 8, patients reporting sleeping an average of 106 minutes more than baseline compared to placebo-treated patients who reported sleeping an average 68 minutes more (P<0.0001). On average, Ambien CR-treated patients reported falling asleep sooner and exhibited improved sleep maintenance based upon fewer nighttime awakenings and decreased wake time after sleep onset compared to placebo-treated patients (P<0.0001). At Week 8, the number of nighttime awakenings decreased in the Ambien CR/escitalopram group (-1.33 + or - 1.26) compared to the placebo/escitalopram group (-0.76 + or - 1.02), and time to sleep onset was reduced 55.1 (+ or - 67.3) minutes with Ambien CR compared to a reduction of 26.8 (+ or - 58.7) minutes with placebo (P<0.0001). In addition, patients reported improvements in secondary measures relating to daytime functioning, including morning energy, morning concentration and sleep impact on daily activities.

Adverse events occurred in 76% of patients treated with Ambien CR/escitalopram and 71% of the patients treated with placebo/escitalopram. The most frequent adverse events experienced by both treatment groups were nausea, dizziness and fatigue. These adverse events have been reported in previous studies of both Ambien CR and escitalopram and are known to be part of the safety profile of both treatments. One patient in each treatment group experienced different serious adverse events.

About Insomnia

Insomnia can be a serious medical condition characterized by difficulty falling asleep, difficulty staying asleep (waking up often during the night and having trouble going back to sleep), waking up too early in the morning and feeling tired upon waking. About 10% of Americans are affected by chronic insomnia each year.

Patients with chronic insomnia report higher ra
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
2. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
3. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
5. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
6. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
7. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
8. Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
9. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
10. Ranbaxy Receives Tentative Approval For Valsartan Tablets
11. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... By Amanda Gardner HealthDay Reporter , MONDAY, July ... evidence proving that staying in shape and eating right are ... that over 8 million Americans have histories of heart attack, ... the message seriously. That,s the theme of a new ...
... about clinical trials for drugs that have been approved ... health risks, an independent committee at the Institute of ... has developed a conceptual framework to guide the agency ... drug-safety trials. The recommendations of the committee, requested ...
... Parkinson disease patients aren,t walking talls ... alleviated with drugs that target dompamine, a chemical in ... and therefore known as a neurotransmitter. However, such drugs ... commonly affect individuals with severe and advanced forms of ...
... Calif., July 12, 2010 UC Irvine public health ... in impoverished reaches of China, Myanmar and Thailand, thanks ... of a seven-year, $14.5 million award to Pennsylvania State ... Diseases. Yan will collaborate with Penn State principal investigator ...
... Drinking tart cherry juice daily could help reduce the severity ... according to a new study published in the Journal ... University of Pennsylvania, University of Rochester and VA Center of ... of 15 older adults. The adults drank 8 ounces of ...
... that roams with only limited control among the rural poor ... cruzi is the triatomine insect, or "kissing bug," which thrives ... sucks the blood of mammals, helping T. cruzi ... to lie on porches or other areas easily accessible to ...
Cached Medicine News:Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 2Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 3Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 2Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 3Health News:JCI online early table of contents: July 12, 2010 2Health News:JCI online early table of contents: July 12, 2010 3Health News:JCI online early table of contents: July 12, 2010 4Health News:JCI online early table of contents: July 12, 2010 5Health News:JCI online early table of contents: July 12, 2010 6Health News:JCI online early table of contents: July 12, 2010 7Health News:JCI online early table of contents: July 12, 2010 8Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Dogs may help collar Chagas disease 2
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) announced ... second quarter dividend of $0.1025 per share. This dividend is payable ... 17, 2011.   ABOUT HILL-ROM HOLDINGS, ... and provider of medical technologies and related services for the health ...
... and SYDNEY, March 7, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, ...
Cached Medicine Technology:HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
Inquire...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
Medicine Products: